Mercado mundial de vacunas contra el rotavirus humano: tendencias de la industria y pronóstico hasta 2030

Análisis y tamaño del mercado de la vacuna contra el rotavirus humano

Los principales factores que se espera que impulsen el crecimiento del mercado de vacunas contra el rotavirus humano en el período de pronóstico son el aumento del desarrollo, el aumento del número de personas inmunocomprometidas y el aumento del estado de alerta entre las personas. Además, el aumento de la población de edad avanzada y el aumento de la población general y de los nacimientos vivos son un par de factores que impulsan aún más el crecimiento del mercado de vacunas contra el rotavirus humano.

Data Bridge Market Research analiza que el mercado mundial de vacunas contra el rotavirus humano, que fue de 7.200 millones de dólares en 2022, se disparará hasta los 10.360 millones de dólares en 2030, y se espera que experimente una CAGR del 6,2% durante el período de pronóstico de 2023 a 2030. Esto indica el valor de mercado. “Rotarix” domina el segmento de tipos del mercado mundial de vacunas contra el rotavirus humano debido al aumento en el número de personas que padecen enfermedades virales. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología de pacientes, análisis de la cartera de productos, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de la vacuna contra el rotavirus humano

Definición de mercado

The Rotavirus vaccine is applied to prevent rotavirus infections which can cause severe diarrhea among young children. Symptoms of rotavirus infection consist of severe diarrhea, vomiting, fever, and abdominal pain, which can cause the disease. The Rotavirus vaccine is given by mouth and requires two or three doses starting around six weeks of age.

Global Human Rotavirus Vaccine Market Dynamics  

Drivers

Advancements in Vaccine Discovery and Manufacturing

Due to advancements in vaccine discovery and manufacturing, the Human Rotavirus Vaccine Market is quickly growing. Furthermore, the market expansion is being fueled by the growing geriatric population as well as raising public awareness.

Increased Vaccine Production

The Human Rotavirus Vaccine Market is expanding due to increased vaccine production. Rotavirus immunization protects children against rotavirus infections, which cause diarrhea. Severe diarrhea, vomiting, fever, and abdominal pain are all indications of rotavirus infection, which can lead to illness. Beginning about the age of six weeks, rotavirus vaccination is given orally in two or three doses.

Opportunities

Increase in Incidences of Human Rotavirus Infection

This increase in incidences is expected to drive the Human Rotavirus Vaccine Market during the forecast period, according to estimates. Various organizations, including UNICEF and GAVI, have urged for the use of the rotavirus vaccine in various countries to enhance immunization coverage and deliver immunizations at a lower cost, hence reducing illness instances and promoting a healthy lifestyle.   

Restraints/Challenges

High cost of vaccines:

The rise in vaccination prices and the vaccine’s unpleasant reactions and side effects would all stymie the market’s growth soon. The potential of bioterrorism and strict regulatory standards for the approval of novel human rotavirus vaccines are the main hindrance to the market.

Recent Development

• In 2017, the Serum Institute of India Pvt. Ltd. revealed the result of a clinical trial Phase 3 efficacy study of the rotavirus vaccine BRV-PV, ROTASIIL. The study has shown that the vaccine is safe, well tolerated, and provides significant efficacy against severe rotavirus gastroenteritis  

Global Human Rotavirus Vaccine Market Scope

The global human rotavirus vaccine market is segmented on the basis of type, application and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Rotarix
• Rotateq
• Rotavac
• Rotavin-M1
• Lanzhou Lamb
• Others

Application

• Hospitals and Clinics
• Academic and Research

End User

• Hospitals and Clinics
• Academic and Research
• Others

Global Human Rotavirus Vaccine Market Regional Analysis/Insights

The global human rotavirus vaccine market is analyzed and market size insights and trends are provided by country, type, application and end user, as referenced above.    

The countries covered in the global human rotavirus vaccine market report are the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa.     

North America is expected to dominate the global human rotavirus vaccine market because of the strong base of healthcare facilities, the strong presence of major players in the market, increasing cases of viral infections and rising number of research activities in this region.      

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, a large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global human rotavirus vaccine market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global human rotavirus vaccine market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global human rotavirus vaccine market. The data is available for the historic period 2015-2020.       

Competitive Landscape and Global Human Rotavirus Vaccine Market Share Analysis

El panorama competitivo del mercado mundial de vacunas contra el rotavirus humano proporciona detalles de los competidores. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado.     

Algunos de los principales actores que operan en el mercado mundial de vacunas contra el rotavirus humano son:  

• Merck & Co., Inc. (Estados Unidos),
• Biotecnología Bharat (India),
• GlaxoSmithKline plc. (Reino Unido),
• Sanofi (Francia),
• Instituto de Productos Biológicos de Lanzhou Co., Ltd (China),
• BIOVIRx Inc (EE. UU.),
• Instituto de suero de la India Pvt. Ltd. (India),
• Biológico E (India),
• Bio Farma (Indonesia),
• Novartis AG (Suiza),
• Instituto de Investigación Médica Berghofer (Australia),
• Pfizer, Inc. (Estados Unidos)

SKU-13241